Placebo of MCI-186

DRUG3 trials

Sponsors

Shionogi

Conditions

Amyotrophic Lateral Sclerosis (ALS)

Phase 3

Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS)

CompletedNCT00330681

ShionogiAmyotrophic Lateral Sclerosis (ALS)

Start: 2006-05-31End: 2008-09-30Updated: 2026-07-21

Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III

CompletedNCT00415519

ShionogiAmyotrophic Lateral Sclerosis (ALS)

Start: 2006-12-31End: 2008-07-31Updated: 2026-07-21

Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS)

CompletedNCT00424463

ShionogiAmyotrophic Lateral Sclerosis (ALS)

Start: 2007-01-31End: 2009-05-31Updated: 2026-07-21

Related Papers

Post-hoc analysis of MCI186-17, the extension study to MCI186-16, the confirmatory double-blind, parallel-group, placebo-controlled study of edaravone in amyotrophic lateral sclerosis

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration2017-09-0539 citations

A Long-Term Safety and Efficacy Extension Study of Patients Diagnosed with Amyotrophic Lateral Sclerosis (ALS) and Treated with Edaravone (MCI-186) (P3.192)

Neurology2016-04-058 citations

A Double-Blind, Parallel-Group, Placebo-Controlled, 24-Week, Exploratory Study of Edaravone (MCI-186) for the Treatment of Advanced Amyotrophic Lateral Sclerosis (ALS) (P3.191)

Neurology2016-04-056 citations